

**TEST CHANGE** 

PM/Scl-100 Antibody, IgG by Immunoblot 2003040, PM/SCL

Specimen Requirements:

**Patient Preparation:** 

Collect: Serum separator tube.

Specimen Preparation: Transfer 1 mL serum to an ARUP <u>standard transport</u>

tube. Standard Transport Tube. (Min: 0.3 mL)

Effective Date: May 20, 2024

Transport Temperature: Refrigerated.

Unacceptable Conditions: Plasma. Contaminated, hemolyzed, or severely lipemic

specimens.

Remarks:

Stability: After separation from cells: Ambient: 48 hours; Refrigerated: 2

weeks; Frozen: 1 month (avoid repeated freeze/thaw

cycles).year

Methodology: Qualitative Immunoblot

Performed: Tue, Thu, Sat

Reported: 1-4 days

Note:

CPT Codes: 86235

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

The presence of PM/Scl-100 IgG antibody along with a positive ANA IFA nucleolar pattern is associated with connective tissue diseases such as polymyositis (PM), dermatomyositis (DM), systemic sclerosis (SSc), and polymyositis/systemic sclerosis overlap syndrome. The clinical relevance of PM/Scl-100 IgG antibody with a negative ANA IFA nucleolar pattern is unknown. PM/Scl-100 is the main target epitope of the PM/Scl complex, although antibodies to other targets not detected by this assay may occur.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Reference Interval:

Negative



Effective Date: May 20, 2024